The use of multiplex polymerase chain reaction (PCR), which is reported to be a reliable molecular method for diagnosing lower respiratory tract infections, has been used increasingly in recent years. The prominent advantage of PCR method compared to culture is that, since PCR is based on replicating the DNA or RNA of very small amount of microorganisms, it does not require living organisms and therefore is not affected by the prior use of antibiotics. In addition, PCR is more sensitive for detection of multiple microorganisms and delivers fast results 4 . Their performances are globally satisfactory, at least for those that are still commercially-available in 2013. Currently many commercial Multiplex diagnostic kits are available in global market with a wide range of common bacterial and viral panel. They vary in their characteristics, number of pathogen detection, degree of multiplexity, number of targets, time required for result, carryover contamination risk, quantification and throughput. Manufacturers are many namely RespPlex, Infinity, Jauar, FilmArray, STAR, PLEX-ID etc5. The overall sensitivity of multiplex PCR for the diagnosis of ALRIs ranged from 56.25% to 91.67% 5 . The potentially important rate of excreters of viral nucleic acids of specific pathogens that are not directly associated with the acute illness presents a problem in this setting. Adenovirus DNA is often found in the respiratory secretions of asymptomatic children. Generally, multiplex-PCR should be used whenever consequences for the treatment will result-for example, stopping a course of antibiotic treatment. So far, there are no algorithms for such an approach that have been validated in practice 6 . Multiplex PCR method is highly reliable and is superior in the detection of multiple pathogens and also provides rapid identification of bacteria and the etiological agents of infection. Therefore widespread use of PCR methods may contribute to the success of LRTI treatments.
